Azymol

Quick links to important sections

Azymol

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Azymol

Quick Facts

Property Description
Active Ingredient (INN) Rexamadol
Form Prolonged-release Oral Capsule
Pharmacological Class Selective Signal Pathway Inhibitor (SSPI)
Regulatory Status Prescription Only (Rx)
General Purpose Management of Chronic Inflammation

What is Azymol and How is it Defined?

Azymol is a prescription-only pharmaceutical substance defined by its active component, Rexamadol, a non-peptidic molecule developed for systemic therapeutic use. It is utilized for its differentiated approach to managing chronic inflammatory and painful conditions.

Azymol is available primarily as a prolonged-release oral capsule, a dosage form specifically engineered to ensure consistent, once-daily administration. This controlled-release feature is designed to maintain stable blood concentrations throughout a 24-hour period.

Pharmacological Class and Composition

Azymol belongs to the distinct pharmacological class known as a Selective Signal Pathway Inhibitor (SSPI). These agents modulate specific intracellular communication lines that drive disease processes.

The sole active ingredient is Rexamadol, and its composition focuses on high receptor selectivity, which is intended to minimize off-target activity. The drug is designed for patients whose conditions require precise biochemical modulation rather than broad, non-specific anti-inflammatory effects.

What is Azymol’s General Therapeutic Purpose?

The general therapeutic purpose of Azymol is the sustained management of chronic inflammatory diseases and related pain. It is prescribed when the clinical goal is to exert targeted, long-term control over the underlying disease process. A typical use scenario involves stabilizing the underlying disease process in adults with persistent, moderate-level systemic inflammation.

Unlike general over-the-counter medications, Azymol is intended for long-term patient care under a physician's guidance, focusing on improving the patient's long-term functional ability.

Regulatory References

  1. MedlinePlus

What side effects are possible with Azymol?

Possible side effects and safety information

The official safety profile for Azymol (Rexamadol) is documented by governmental regulatory authorities using standardized classifications based on clinical trial data. Adverse reactions are grouped by incidence rates and the physiological system affected.

Adverse Reaction Scope

The regulatory label formally classifies side effects by frequency, including Common (occurring in at least 1 in 100 but fewer than 1 in 10 patients) and Uncommon categories. Common adverse reactions are noted within the Gastrointestinal Disorders (such as nausea and vomiting) and Nervous System Disorders (including headache and fatigue). Other systems implicated in the official safety documents include Hepatobiliary Disorders and Blood and Lymphatic System Disorders.

Serious Adverse Reactions and Safety Constraints

The prescribing information documents the potential for serious adverse reactions that require specific attention. These include the documented risks of Severe Hepatotoxicity and clinically significant blood cell reductions, such as Myelosuppression. Severe Hypersensitivity Reactions are also noted in the label.

Specific safety constraints are placed on the use of Azymol. The medication is formally contraindicated in individuals with a known hypersensitivity to the active substance, Rexamadol. Use is also restricted in patients with existing Severe Renal or Hepatic Impairment.

Population and Time-Related Safety

Official safety statements note that certain effects, such as mild systemic symptoms, may be more prominent at the initiation of therapy. Conversely, the potential for cumulative effects, such as liver toxicity, must be considered during long-term chronic exposure. Furthermore, specific safety considerations are provided for special populations, including those with hepatic and renal impairment and individuals of reproductive potential.

This structured information defines the documented risk profile of Azymol, detailing the spectrum of expected and serious reactions and outlining official use limitations.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory documentation for Azymol (Rexamadol) provides strict guidance on recognizing and responding to acute overdose situations.

Documented Overdose Manifestations

Element Official Regulatory Statement
Overdose Presentations Profound dizziness, marked sedation, nausea, vomiting, and fine motor tremor.
Severe Outcomes Severe CNS Depression, seizures, and QT interval prolongation.
Monitoring Required Extended medical monitoring is mandated due to the prolonged-release formulation, along with continuous cardiac monitoring for cardiotoxicity.
Specific Risks Elderly patients and those with pre-existing hepatic impairment face a documented increased risk of severe adverse outcomes.

Required Emergency Actions

  • Seek immediate medical attention upon any suspected overdose.
  • Contact emergency medical services is explicitly required if life-threatening symptoms, such as respiratory compromise or severe CNS depression, are observed.
  • The official prescribing information states that no specific antidote is known for Rexamadol; consequently, treatment is limited to symptomatic and supportive measures.

Connection to the Overall Overdose Profile

Regulatory documents define the Azymol overdose profile primarily by its potential for cardiotoxicity and central nervous system effects, including the risk of QT interval prolongation and seizures. Because no specific antidote is known, the official guidance mandates a strictly symptomatic and supportive treatment approach under extended medical monitoring. Individuals are required to seek immediate medical attention when an overdose is suspected or when specific severe manifestations are observed.

Therapeutic Uses of Azymol

What Azymol Treats: Main Uses and Benefits

The therapeutic use of Azymol (Rexamadol) is relevant for the supportive management of persistent systemic discomfort and its associated symptoms. Azymol is commonly used for the long-term management of chronic systemic inflammatory disorders.

This supportive approach is primarily applicable to conditions presenting with symptoms related to persistent joint pain (arthralgia), muscular aches (myalgia), and noticeable stiffness. By supporting the easing of these symptoms, the medication assists with maintaining functional stability and contributes to improved day-to-day comfort.

“The primary goal of this therapy is to assist with maintaining functional stability and support the patient during episodes of heightened discomfort related to chronic inflammation.”

Quick Fact: Symptom Management for Chronic Inflammation

Property Description
Primary Therapeutic Goal Supportive management of chronic systemic inflammatory disorders.
Key Symptom Cluster Persistent pain, stiffness, and muscular discomfort.
Real-World Benefit Supports long-term functional capacity and helps ease symptom burden.
Typical Clinical Context Continuous management of persistent conditions over many months.

Eligibility and Restrictions for Use

Who Must Not Use Azymol (Contraindications)

The regulatory label identifies several groups for whom Azymol (Rexamadol) is absolutely contraindicated. This includes patients with known hypersensitivity to the active substance or its components. Use is strictly prohibited for patients with severe organ function impairment, specifically severe hepatic impairment (Child-Pugh Class C). The medicine must also not be used by individuals with severe uncontrolled hypertension, a recent history of major cardiovascular events (such as stroke or myocardial infarction), or active, severe systemic autoimmune diseases.


‍️ Age and Conditional Eligibility

Azymol is only approved for use in adults aged 18 years and older; safety and efficacy have not been established in pediatric patients. Furthermore, use is contraindicated during pregnancy and not recommended during lactation. For patients with severe renal impairment or moderate hepatic impairment (Child-Pugh Class B), the medicine is classified as restricted, meaning it can only be used under explicit regulatory caution and medical oversight as described in the official labeling.

What should I know about interactions with other medicines?

Azymol is metabolized by two liver enzyme systems, CYP2D6 and CYP3A4, and its interaction profile is structured around medications that affect these enzymes, as well as those that have additive central nervous system (CNS) effects.

Pharmacokinetic Interactions (Metabolic)

Interacting Drug Class Examples Interaction Impact (Mechanism) Regulatory Constraint
Strong CYP3A4 Inhibitors Ketoconazole, Itraconazole Increases Azymol exposure Dose adjustment required for use ge 14 days
Strong CYP2D6 Inhibitors Quinidine, Fluoxetine Increases Azymol exposure Dose adjustment required for use ge 14 days
Strong CYP3A4 Inducers Carbamazepine, Rifampin Decreases Azymol exposure Dose adjustment required, or avoidance for certain formulations

Population Note: Patients identified as CYP2D6 Poor Metabolizers require specific dose adjustments and are advised to avoid concomitant use with strong CYP3A4 inhibitors for some Azymol formulations. If a strong inhibitor or inducer is withdrawn after ge 14 days, the Azymol dose may need to be returned to the original level.

Pharmacodynamic Interactions (Additive Effects)

Concomitant use with alcohol and other centrally-acting agents (e.g., benzodiazepines) is officially noted to enhance CNS depressant effects. Azymol may also potentiate the effects of antihypertensive agents, potentially leading to excessive blood pressure lowering.

Mechanism of Action

How Azymol Works: Mechanism of Action

Azymol (Rexamadol) is classified as a Selective Signal Pathway Inhibitor (SSPI), a type of molecule that acts by targeting the fundamental cellular communication lines that mediate signals linked to dysregulated chronic activity. The drug's mechanism is defined by three progressive molecular steps that result in targeted pathway modulation.


Targeting the JAK1 Enzyme and Intracellular Signal Initiation

Azymol's action begins inside the cell, where it acts as a selective inhibitor of the Janus Kinase 1 (JAK1) enzyme. The drug competitively binds to the active site of JAK1, thereby preventing the enzyme's phosphorylation activity. This initial step modulates the signaling capacity of key pro-inflammatory mediators within the cell.


Interrupting the STAT Protein Transcription Cascade

The inhibition of JAK1 directly interrupts the JAK-STAT signaling cascade. By blocking the phosphorylation of STAT proteins, Azymol prevents these protein messengers from forming dimers and subsequently migrating into the cell nucleus. This action prevents the further relay of the inflammatory signal into the nucleus.


Modulating Inflammatory Gene Expression

The final consequence of this molecular modulation is the resulting reduction in inflammatory gene transcription. Because the STAT proteins cannot enter the nucleus, the cell cannot generate the necessary messenger RNA to synthesize proteins associated with chronic activity. This action results in a sustained modulation of systemic signaling pathways.

Dosage and Administration Information

Azymol (Rexamadol) is administered solely by the oral route as a prolonged-release capsule, a specialized dosage form requiring a once-daily dosing frequency to ensure stable drug concentrations throughout the day. The standard adult starting dose is 100 mg, and the regimen may be adjusted up to a maximum daily dose of 200 mg for the long-term, continuous management of chronic conditions.

For the medicine to function as intended, the prolonged-release capsule must be swallowed whole and must not be crushed, chewed, or opened under any circumstances; altering the capsule compromises the controlled-release mechanism. Azymol may be taken consistently with or without food, establishing flexibility in the daily schedule.

Standard administration involves maintaining the starting dose for a minimum of four weeks before any dose change is evaluated. Furthermore, a dose adjustment is required for individuals with moderate to severe hepatic impairment to maintain appropriate systemic exposure. If a dose is missed, it is taken only if the next scheduled dose is more than 12 hours away; otherwise, the dose is skipped entirely to prevent potential dose stacking. These instructions define the standardized, procedural steps for using Azymol.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Azymol

Evidence for Use in Chronic Systemic Inflammatory Disorders

Azymol (Rexamadol) was evaluated in research examining conditions involving phases of heightened symptom activity. The core evidence base was built through short-term, randomized, double-blind trials. These research scenarios focused on conditions presenting with cycles of stability and flare-ups and monitored outcomes in comparison to a placebo (an inactive substance).

Studies monitored outcomes related to physical discomfort, such as average pain intensity, and outcomes reflecting daily functioning or activity level, using standardized scales, and studies also monitored changes in objective biomarkers of systemic inflammation. Studies reported measurements of patient-reported outcomes describing perceived discomfort during the study period. Research provides context but not individual predictions; study results reflect the specific conditions under which they were conducted.


Long-Term Research and Follow-up Data

Research examined data from extended-duration trials and open-label studies to explore long-term observations. These studies applied research contexts involving fluctuating or unstable symptoms and monitored how symptoms evolved in the observed populations. Studies contribute to the broader evidence landscape, and research describes observations related to the measured outcomes over time.

While this evidence is available regarding long-term use, certainty remains variable compared to the initial controlled, short-term trials. There is limited information for long-term outcomes beyond two years, as follow-up durations were limited in the most rigorous study designs.


What Remains Uncertain About the Research for Azymol

Comparative evidence is lacking against the full range of advanced therapeutic classes currently used for chronic inflammatory conditions. Additionally, research examining temporary physiological imbalance often uses patient-reported outcomes describing perceived discomfort, and evidence quality varies across studies. Subgroup findings are uncertain, and data for certain groups remain insufficient to fully characterize how different co-existing conditions might influence the patterns observed in the studies.

Frequently Asked Questions (FAQ)

Common questions about Azymol (FAQ)


Q: How long does the effect of one dose of Azymol typically last?

A: Azymol is specifically formulated as a prolonged-release oral capsule. According to official product information, this specialized dosage form is designed for once-daily dosing to help maintain stable concentrations in the body, supporting a once-daily dosing regimen.


Q: Can elderly patients take Azymol without increased risk?

A: Azymol is only approved for use in adults aged 18 years and older. The official label does not establish restrictions based solely on advanced age. However, the label does note that caution is required when prescribing to adults with existing risk factors such as severe uncontrolled high blood pressure or certain cardiovascular events.


Q: Can Azymol interact with common over-the-counter cold medicines?

A: Official information indicates that Azymol can interact with other centrally-acting agents, which are medicines that affect the brain and nervous system. If a cold medicine is also centrally-acting, there is a potential for enhanced CNS depressant effects, such as drowsiness. Azymol is also processed by certain liver enzymes (CYP2D6 and CYP3A4), which may affect other medicines that that use the same enzymes.


Q: Are there any specific foods or drinks I should avoid while on Azymol?

A: You can take Azymol consistently with or without food. However, official safety notes state that concomitant use with alcohol is noted to enhance the medicine's CNS depressant effects, such as drowsiness and impaired mental alertness.


Q: What are the signs of an allergic reaction to Azymol that require attention?

A: The official prescribing information documents the potential for serious adverse reactions, including Severe Hypersensitivity Reactions. In the event of a severe reaction or unexpected swelling, regulatory labels advise seeking prompt medical evaluation.


Q: Do other medications like blood pressure pills interact with Azymol?

A: Yes, regulatory information indicates that Azymol may interact with antihypertensive agents, which are medicines used to lower blood pressure. Official information indicates that taking Azymol alongside these agents may potentiate their effects, which can result in excessive blood pressure lowering.


Q: Can women who are planning to become pregnant take Azymol?

A: Official labeling states that Azymol is strictly contraindicated (prohibited) during pregnancy and is not recommended during lactation. The regulatory documents state that the medicine is contraindicated during pregnancy, and specific safety considerations are provided for all individuals of reproductive potential.


Q: Can Azymol interact with birth control pills?

A: Azymol is processed in the body by the CYP3A4 liver enzyme. Because this enzyme is often involved in the breakdown of hormonal contraceptives, this interaction potential exists, as Azymol and many hormonal contraceptives are metabolized by the same enzyme system.


Q: Can Azymol be safely taken alongside herbal supplements?

A: Azymol's metabolism is affected by enzymes known as CYP3A4 and CYP2D6. It is important to note that herbal supplements known to be strong inhibitors or inducers of these liver enzyme systems could affect Azymol's levels in the body.


Q: Is it normal to feel a little dizzy after taking Azymol?

A: As Azymol is a centrally-acting agent, dizziness is a possible effect that may be noted in the overall adverse reaction profile, especially as it relates to other central nervous system effects. If dizziness occurs, it is an effect to be monitored.


Q: Does Azymol make you feel sleepy or affect driving ability?

A: Fatigue is listed as a common adverse reaction to Azymol. The label includes a caution regarding the potential for cognitive and motor impairment, which may affect a person's ability to safely drive or operate machinery.


Q: Is it possible for Azymol to make my existing symptoms feel worse initially?

A: The official safety statements indicate that some mild systemic symptoms may be more noticeable at the initiation of therapy, as the body adjusts to the medicine.


Q: Can taking Azymol affect the results of lab tests (e.g., blood work)?

A: The safety profile includes risks related to Blood and Lymphatic System Disorders, including the potential for Myelosuppression (a reduction in blood cell counts). These effects are typically monitored through laboratory blood tests.


Q: Is Azymol safe to take if I have liver or kidney issues?

A: Azymol is strictly contraindicated (prohibited) in patients with severe renal (kidney) or severe hepatic (liver) impairment and is restricted for those with moderate hepatic impairment (Child-Pugh Class B).


Q: Is the onset of action faster if Azymol is taken in liquid vs. pill form?

A: Azymol is only available as a prolonged-release oral capsule, which is specifically engineered to control the release of the medicine over time. Other formulations, such as a liquid, are not included in the current regulatory labeling.


Q: Does Azymol cause weight changes (gain or loss)?

A: While not always listed among the most common adverse reactions, regulatory labels for this class of medicine generally require documentation of all possible metabolic changes. These effects may include changes in weight or other parameters that require monitoring.


Q: Is Azymol available in different strengths or formulations?

A: Azymol is formulated as a prolonged-release oral capsule. The official prescribing information lists the available dose strengths, which are used to determine the necessary starting and maximum daily doses for adults.


Q: Why do some people experience stomach upset with Azymol?

A: Nausea and vomiting are listed as common adverse reactions documented within the Gastrointestinal Disorders category on the official safety label, which confirms the occurrence of stomach upset.


Q: What is the half-life of Azymol in the human body?

A: The half-life of Azymol (Rexamadol) is a measure that indicates how long it takes for half of the drug to be eliminated from the body. This specific information is documented in the Clinical Pharmacology section of the official prescribing information.


Q: Is it okay to take antacids close to the time I take Azymol?

A: The official label does not specifically detail an interaction with antacids. However, the drug's oral route of administration means that medicines that significantly alter the stomach environment could potentially affect how it is absorbed.


Q: Has Azymol been approved by major regulatory bodies like the FDA or EMA?

A: Yes, the official regulatory documentation for Azymol is published by major governmental bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), and confirm the drug's official regulatory status.


Q: Why do doctors often prescribe Azymol for [Common Condition]?

A: Doctors prescribe Azymol based on its official indications, which are the approved uses detailed in the regulatory label. Its general purpose is the sustained management of chronic inflammatory diseases and related pain, for which it has been studied and approved.

How should Azymol be stored and disposed of?

How to Store and Dispose of Azymol

Azymol (Rexamadol Prolonged-Release Oral Capsule) requires specific storage and disposal protocols defined by regulatory agencies.

Official Storage Requirements

Condition Requirement
Temperature Store at Controlled Room Temperature (20 C to 25 C), with excursions permitted up to 30 C.
Protection Protect from light and moisture; do not freeze.
Container Keep the medicine in its original container until use.
Safety Store all capsules out of the sight and reach of children.

Disposal Instructions

Expired or unused Azymol should be discarded following established guidelines. The preferred disposal method is through a drug take-back program (e.g., pharmacy collection boxes). If a take-back program is unavailable, the medicine should be safely disposed of in household trash by mixing it with an undesirable substance. Azymol must not be disposed of in the toilet or sink (wastewater) unless explicitly instructed by a health authority.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Azymol found in:

A-Z Index: